These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31649165)

  • 1. Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate.
    Sarayani A; Albogami Y; Elkhider M; Hincapie-Castillo JM; Brumback BA; Winterstein AG
    BMJ Qual Saf; 2020 Aug; 29(8):636-644. PubMed ID: 31649165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.
    Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG
    Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.
    Sarayani A; Donahoo WT; Hampp C; Brown JD; Winterstein AG
    Ann Intern Med; 2023 Apr; 176(4):443-454. PubMed ID: 36940443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk evaluation and mitigation strategies: a focus on the mycophenolic acid preparations.
    Rostas S; Kim M; Gabardi S
    Prog Transplant; 2014 Mar; 24(1):33-6. PubMed ID: 24598563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies.
    Kim M; Rostas S; Gabardi S
    Am J Transplant; 2013 Jun; 13(6):1383-9. PubMed ID: 23617812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the quality of drug safety information for patients: An analysis of REMS educational materials.
    Chan HW; Russell AM; Smith MY
    Pharmacoepidemiol Drug Saf; 2018 Sep; 27(9):969-978. PubMed ID: 30003610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S
    Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
    Hollingsworth K; Romney MC; Crawford A; McAna J
    J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.
    Toyserkani GA; Huynh L; Morrato EH
    Front Public Health; 2020; 8():43. PubMed ID: 32158741
    [No Abstract]   [Full Text] [Related]  

  • 10. A guide to understanding and implementing risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S; Tichy EM
    Prog Transplant; 2013 Mar; 23(1):58-62; quiz 63. PubMed ID: 23448822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk evaluation and mitigation strategies (REMS): educating the prescriber.
    Nicholson SC; Peterson J; Yektashenas B
    Drug Saf; 2012 Feb; 35(2):91-104. PubMed ID: 22171604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
    Slevin KA; Ashburn MA
    J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.
    Gabardi S
    Prog Transplant; 2013 Mar; 23(1):55-7. PubMed ID: 23448821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive Health Care for Female Adolescents Prescribed Mycophenolate at a Children's Hospital: A 10-Year Retrospective Cohort Study.
    Al-Husayni N; Maslyanskaya S; Rubinstein TB; Coupey SM
    J Pediatr; 2023 Feb; 253():252-258. PubMed ID: 36208664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction.
    Wu J; Juhaeri J
    Clin Ther; 2016 Dec; 38(12):2526-2532. PubMed ID: 27914632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.
    American Pharmacists Association ; Bough M
    J Am Pharm Assoc (2003); 2011; 51(3):340-58. PubMed ID: 21555285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018).
    Huynh L; Toyserkani GA; Morrato EH
    BMC Health Serv Res; 2021 Aug; 21(1):779. PubMed ID: 34362367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: A retrospective cohort study.
    Thai TN; Sarayani A; Wang X; Albogami Y; Rasmussen SA; Winterstein AG
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):716-724. PubMed ID: 32347619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the impact of the extended-release/long-acting opioid an-algesics risk evaluation and mitigation strategies on opioid prescrip-tion volume.
    Divino V; Cepeda MS; Coplan P; Maziere JY; Yuan Y; Wade RL
    J Opioid Manag; 2017; 13(3):157-168. PubMed ID: 28829517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.